Cargando…

Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings

Background This study aimed to understand the attitudes, beliefs, and concerns of physicians across India regarding the economic burden of diabetes and subsequently the cost-effectiveness of low-cost dapagliflozin for the management of patients with uncontrolled type 2 diabetes mellitus (T2DM) on ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Kamal, Chandorkar, A B, Kovil, Rajiv, Venkataraman, S, Subrahmanyam, KAV, Mandal, Parthasarathi, Wasir, Jasjeet, Abhyankar, Mahesh, Prasad, Ashish, Sarda, Prashant S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642133/ https://www.ncbi.nlm.nih.gov/pubmed/34877189 http://dx.doi.org/10.7759/cureus.19194

Ejemplares similares

Management of Diabetic Foot in an Indian Clinical Setup: An Opinion Survey
por: Das, Ashok, et al.
Publicado: (2020)

Best Practices and Tools for Titrating Basal Insulins: Expert Opinion from an Indian Panel via the Modified Delphi Consensus Method
por: Jain, Sunil M., et al.
Publicado: (2020)

Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
por: Chadha, Manoj, et al.
Publicado: (2022)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
por: Iqbal, Iqra, et al.
Publicado: (2019)

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
por: Brown, Emily, et al.
Publicado: (2021)

Use of insulin degludec/aspart after resolution of euglycemic diabetic ketoacidosis associated with dapagliflozin in a female patient with newly diagnosed maturity onset diabetes of the young type 3
por: Ayhan, Ihsan, et al.
Publicado: (2023)

LBSUN207 Efficacy And Safety Of Degludec U100 Versus Glargine U300 For The Hospital Management Of Patients With Type 2 Diabetes: A Prospective, Open-label, Non-inferiority Randomized Controlled Trial
por: Kuchay, Mohammad Shafi, et al.
Publicado: (2022)

Experts Opinion
por: Goldberg, Ivan, et al.
Publicado: (2012)

Expert Opinion
Publicado: (1920)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
por: Chen, Jung-Fu, et al.
Publicado: (2020)

Essentials of pharmacoeconomics
por: Rascati, Karen L.
Publicado: (2014)

Principles of pharmacoeconomics /
Publicado: (1996)

LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes
por: Ghanim, Husam, et al.
Publicado: (2022)

PSUN259 A Severe Case of Fournier's Gangrene Associated With Dapagliflozin
por: Syed, Shumail, et al.
Publicado: (2022)

LBSUN291 Fournier's Gangrene In A Diabetic Male Taking Dapagliflozin
por: Patel, Janki M, et al.
Publicado: (2022)

Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India
por: Wasir, Jasjeet S., et al.
Publicado: (2018)

Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion
por: Das, Ashok K., et al.
Publicado: (2021)

Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
por: Khan, Sarfaraz, et al.
Publicado: (2022)

Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report
por: Gupta, Sushan, et al.
Publicado: (2023)

Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion
por: Hiremath, Jagdish, et al.
Publicado: (2023)

More Expert Opinion
Publicado: (1920)

The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan
por: Kamin, Matiullah, et al.
Publicado: (2020)

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
por: Bawa, Tarunika, et al.
Publicado: (2013)

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
por: Singh, Jagdeep S.S., et al.
Publicado: (2020)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis
por: Wang, Qianwen, et al.
Publicado: (2022)

Heart Rate in Hypertension: Review and Expert Opinion
por: Dalal, Jamshed, et al.
Publicado: (2019)

Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial)
por: Færch, Kristine, et al.
Publicado: (2017)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

FRI649 ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control
por: Phadke, Dr Uday, et al.
Publicado: (2023)

Patellofemoral arthroplasty: expert opinion
por: Hoogervorst, Paul, et al.
Publicado: (2022)

Pharmacoeconomics in COPD: lessons for the future
por: Starkie, Helen J, et al.
Publicado: (2008)

Fluid management: the pharmacoeconomic dimension
por: Vincent, Jean-Louis
Publicado: (2000)

Drug Policy Research & Pharmacoeconomics
Publicado: (2008)

Development of pharmacoeconomics guidelines for India
por: Thomas, Dixon, et al.
Publicado: (2014)

Formulary Management Methods and Pharmacoeconomics
por: Curtiss, Frederic R.
Publicado: (2003)

Pharmacoeconomic Benefits of Antihypertensive Therapy
por: Gonzalez, Edgar R.
Publicado: (2007)

Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
por: Das, Chandan, et al.
Publicado: (2021)

Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
por: Benjamin, Silas, et al.
Publicado: (2021)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_enrlhah37l15ppjg5c09nap02o